ClinicalTrials.gg
RecruitingNCT06744322DISCHARGE-MIUpdated Mar 16, 2026

Fast Discharge After Acute Myocardial Infarction Discharge MI

An interventional study of Fast discharge strategy in Acute Myocardial Infarction (AMI), sponsored by Medical University Innsbruck. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Medical University Innsbruck · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,070
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Myocardial Infarction with a site in Austria — 8 open to participants now, 12 under way, 5 of them phase 3. Myocardial Infarction · Austria.

Planned enrollment
16th of 35
2,070 · median 1,875
Started
2024
with 2 others
No phase
10 of 48
2 open now
Primary completion
2029-12
later than 10 of 11 live
Registered
44th of 48
by date

Among the 48 studies in Myocardial Infarction with a site in Austria, this one is the 16th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 44th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

8 of the 48 studies in Myocardial Infarction with a site in Austria are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Myocardial Infarction with a site in Austria, or all of them as a file.
02

Study summary

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

Read the detailed description

The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge >36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.

03

Conditions studied

  • Acute Myocardial Infarction (AMI)

Keywords

  • Myocardial Infarction
  • STEMI
  • NSTEMI
  • Discharge
  • Randomized
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
  • Age ≥ 18 years at time of consent
  • Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
  • Ability to understand and willingness to sign and date written

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
  • PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
  • Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
  • Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
  • Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
  • Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
  • Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
  • Pregnancy
  • Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
  • Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,070 participants (estimated)

Study arms

  • No intervention
    Standard Care

    Patients undergo a standard post-infarction care, with discharge at \>36 hours after invasive management of acute myocardial infarction.

  • Experimental
    Fast discharge strategy

    Fast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction.

    Procedure: Fast discharge strategy

Interventions

  • ProcedureFast discharge strategy

    Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.

06

What researchers measure

Primary outcomes

  1. MACE

    MACE is defined as a composite of all-cause death, myocardial re-infarction and unscheduled cardiovascular re-hospitalization.

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

Secondary outcomes

  1. All cause death

    Death from any cause.

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  2. Number of participants with myocardial re-infarction

    Number of participants experiencing myocardial re-infarction

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  3. Number of participants with unscheduled cardiovascular re-hospitalization

    Number of participants with unscheduled cardiovascular re-hospitalization

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  4. Number of participants with Cardiovascular death

    Number of participants experiencing cardiovascular-related death

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  5. Number of participants hospitalized for heart failure

    Number of participants hospitalized for heart failure

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  6. Number of participants expiring hospitalization from any cause

    Number of participants expiring hospitalization from any cause

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  7. Number of patients experiencing a stroke

    Number of patients experiencing a stroke

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  8. Number of participants with a bleeding event

    Number of participants with a bleeding event

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  9. Healthcare costs per patient between randomization and 12 months

    An economic evaluation will be conducted from the healthcare payer perspective. Direct healthcare costs, including intervention costs, hospitalizations, outpatient visits, diagnostic procedures, and concomitant medications, will be collected prospectively for each participant over the study period. Mean total healthcare costs per patient will be calculated and compared between study groups.

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  10. Length of hospital stay

    Number of days in hospital from time of infarction to hospital discharge

    Time frame: From the date of randomization to the date of hospital discharge, for up to 100 days

  11. Percentage of patients on guideline-directed therapy

    Percentage of patients on guideline-directed therapy

    Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).

  12. Infection

    Infection leading to hospitalization

    Time frame: At 30 days

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2029, 60 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 60 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 20, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06744322
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Dec 1, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 16, 2026

Study contacts

Martin Reindl, MD, PhD
Contact
martin.reindl@tirol-kliniken.at
+43 512 504 25665
Ivan Lechner, MD, PhD
Contact
ivan.lechner@tirol-kliniken.at
Martin Reindl, MD, PhD
principal investigator · Medical University Innsbruck
Sebastian J Reinstadler, MD, PhD
principal investigator · Medical University Innsbruck

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion